Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- LATUDA Meets Efficacy Endpoints in 3rd PIII Trial
November 15, 2010
- Lurasidone Approval “Exceptionally Quick”: DSP President Tada
November 15, 2010
- Zyvox Shows Higher Success Rate than Vancomycin: Pfizer
November 15, 2010
- Applications Based on Data from Public Domain Recommended for 3 APIs by 2nd Committee
November 8, 2010
- Injectable Cravit Approved: Daiichi Sankyo
November 8, 2010
- Generics Show Big Differences in Market Share Depending on Therapeutic Category
November 8, 2010
- Price Settlement Not Expected before End December for 26.2% of Sales: NPhA
November 8, 2010
- 6 APIs Recommended for Application Based on Data from Public Domain by 1st Committee
November 8, 2010
- Astellas Applies for Degarelix in Japan
November 8, 2010
- tella, CreaGene Sign MOU to Jointly Develop Dendritic Cell Vaccine Therapy
November 8, 2010
- Takeda: Sales, Profits Down Due to Takepron Patent Expiration
November 8, 2010
- 14-Day Limit on Prescription of New Drugs to Be Relaxed for Combination Drugs
November 8, 2010
- Eli Lilly Applies for Bipolar Disorders for Zyprexa
November 8, 2010
- Daiichi Sankyo: Sales Up 6.0% Due to Recovery of Ranbaxy Business
November 8, 2010
- Chuikyo to Review Combinations of Insurance-Covered, Non-Covered Healthcare Services
November 8, 2010
- MSD Applies for Coadministration of Sitagliptin, Insulin
November 8, 2010
- Eisai: Record-High Profits Driven by Aricept
November 8, 2010
- Korosho to Take Advantage of Kohdo-Iryo System to Eliminate Drug Lag
November 8, 2010
- Chugai Applies for Pegasys, Copegus Combination Therapy
November 8, 2010
- MTPC: Remicade Drives Business with 29% Increases in Sales
November 8, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…